Holen Sie sich die Stockscreener-App
68.12
1.95%
1.30
Handel nachbörslich:
68.12
Disc Medicine Inc Aktie (IRON) Neueste Nachrichten
Disc Medicine Eyes Mid-2026 Bitopertin Approval as EPP Trial Demand Surges - Yahoo Finance
Class action lawsuit launched over Disc Medicine's FDA drug rejection causing 22% stock drop - Pluang
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are ... - Caledonian Record
IRON Investor News: If You Have Suffered Losses in Disc - GlobeNewswire
Why (IRON) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Eagle Health Investments LP Purchases Shares of 27,100 Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine faces class action after FDA rejects drug application, stock drops 22%. - Pluang
IRON: APOLLO study enrollment exceeded targets, signaling high demand and unmet need for EPP therapies - TradingView
DNB Asset Management AS Raises Stock Holdings in Disc Medicine, Inc. $IRON - MarketBeat
First Light Asset Management, LLC's Disc Medicine Inc(IRON) Holding History - GuruFocus
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inqui - GuruFocus
Disc Medicine faces class action after FDA rejects drug application, stock drops 22% - Pluang
Rosen Law Firm Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - The Norfolk Daily News
UBS Group AG Reduces Holdings in Disc Medicine, Inc. $IRON - MarketBeat
Should Disc Medicine’s RALLY-MF Data and Wider Pipeline Reveal a Pivotal Inflection for IRON’s Narrative? - simplywall.st
Disc Medicine, Inc.Common Stock (NQ: IRON - FinancialContent
IRON Maintained by Morgan Stanley -- Price Target Raised to $80. - GuruFocus
Cantor Fitzgerald Remains a Buy on Disc Medicine (IRON) - The Globe and Mail
Morgan Stanley Raises Price Target on Disc Medicine to $80 From $75, Keeps Overweight Rating - marketscreener.com
Understanding Momentum Shifts in (IRON) - Stock Traders Daily
IRON Investor News: If You Have Suffered Losses in Disc Medicine, Inc. (NASDAQ: IRON), You Are Encouraged to Contact The Rosen Law Firm About Your Rights - GlobeNewswire Inc.
Disc Medicine, Inc. Announces Oral Presentation of Phase 2 RALLY-MF Trial Data for DISC-0974 at EHA 2026 Congress and Corporate Update Call - Quiver Quantitative
Experimental anemia treatment shows 70% response in myelofibrosis trial - Stock Titan
Vanguard Group Inc. Acquires 319,621 Shares of Disc Medicine, Inc. $IRON - MarketBeat
Disc Medicine to present multiple hematology tr... | Pluang – Crypto, Stocks, Gold & Funds - Pluang
Stifel Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $111 - Moomoo
Hear Disc Medicine leaders in two live investor conference webcasts - Stock Titan
Disc Medicine to Participate in Upcoming Investor Conferences - FinancialContent
Number of shareholders of Disc Medicine, Inc. – NASDAQ:IRON - TradingView
Press releases provided by CNW - Techaeris
A Look At Disc Medicine (IRON) Valuation As Key APOLLO Phase 3 And Pipeline Milestones Progress - Sahm
Disc Medicine, Inc. (IRON) Eps Diluted (TTM) - Zacks Investment Research
HC Wainwright Cuts Earnings Estimates for Disc Medicine - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Disc Medicine, Inc.IRON - PR Newswire
Disc Medicine FY2030 EPS Forecast Raised by HC Wainwright - MarketBeat
H.C. Wainwright Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $118 - Moomoo
Disc Medicine (IRON) Receives a Buy from H.C. Wainwright - The Globe and Mail
BMO Capital Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Truist Financial Maintains Disc Medicine(IRON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
A Look At Disc Medicine (IRON) Valuation After Legal Probes And FDA Complete Response Letter - Yahoo Finance
Disc Medicine Q1 Net Loss Widens - Moomoo
Disc Medicine (NASDAQ:IRON) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS - MarketBeat
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, vs. FactSet Est of $1.65 Loss - marketscreener.com
Disc Medicine (NASDAQ: IRON) posts wider Q1 loss but holds $730M cash - Stock Titan
Disc Medicine 1Q 2026: Net income $(63.5M), EPS $(1.65) — 10-Q Summary - TradingView
Earnings Flash (IRON) Disc Medicine Posts Q1 Net Loss $1.65 a Share, Vs. FactSet Est of $1.65 Loss - Moomoo
IRON: Phase 3 bitopertin trial enrollment completed; strong cash position supports pipeline into 2029 - TradingView
Disc Medicine finishes Phase 3 rare-disease trial, eyes Q4 data - Stock Titan
IRON: Net loss widened to $63.5M in Q1 2026 as bitopertin's FDA review was delayed for more data - TradingView
Disc Medicine (NASDAQ: IRON) posts Q1 2026 loss and advances late-stage trials - Stock Titan
Disc Medicine | 8-K: Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update - Moomoo
How Investors Are Reacting To Disc Medicine (IRON) After FDA Letter Triggers Shareholder Investigation - simplywall.st
ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Disc Medicine, Inc. Investors to Inquire About Securities Class Action InvestigationIRON - TMX Newsfile
Avoiding Lag: Real-Time Signals in (IRON) Movement - Stock Traders Daily
Disc Medicine, Inc. $IRON Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):